Economics of Prostate Cancer in Canada: A Systematic Review
Author(s)
Félix Morin, BSc1, Bougchiche Meïssa, BSc1, Ivan Yanev, BSc, MSc2, Alice Dragomir, PhD1;
1Faculté de pharmacie, Université de Montréal, Montréal, QC, Canada, 2Department of Surgery, McGill University, Montréal, QC, Canada
1Faculté de pharmacie, Université de Montréal, Montréal, QC, Canada, 2Department of Surgery, McGill University, Montréal, QC, Canada
Presentation Documents
OBJECTIVES: Prostate cancer (PCa) is the most common cancer and the third leading cause of death from cancer among Canadian men. Since 2012, new treatments with higher costs have been implemented in Canada, increasing the financial pressure of PCa management. The objective of this study is to review the scientific literature identifying management costs of PCa in Canada.
METHODS: A systematic review was conducted across Embase, MEDLINE, CINHAL, Web of Science and grey literature of studies presenting Canadian costs of PCa management. Eligible studies included studies presenting direct or indirect Canadian costs of PCa management, including pharmacological or non-pharmacological treatments, adverse events management and diagnosis. The CHEC criteria list was used for quality assessment of the studies. Study selection, data extraction and quality assessment were conducted independently by two reviewers. Costs were standardized to 2023 Canadian dollars using the Statistic Canada’s Consumer Price Index for health and personal care.
RESULTS: 28 studies were retrieved and analyzed. Costs presented covered various aspects of PCa management like radical prostatectomy (8 studies, $9,123.86 - $24,583.19 per case), radiation therapy (10 studies, $4,156.21 - $21,388.73 per case), androgen deprivation therapy (6 studies, $4,560.21 - $41,776.08 per year) or management of metastatic bone disease (3 studies, $6,490.37 - $27,078.37 per year). While the more ancient management methods are well documented, literature remains sparse when it comes to the new treatments for PCa like enzalutamide (2 studies, $26,653.32 - $47,351.08 per year) or abiraterone (2 studies, $47,336.16 - $53,547.92).
CONCLUSIONS: This is the first systematic review of Canadian costs of PCa management since 2013. Even though the data on the newer therapies is still limited, we can conclude that they are costlier and add to the economic burden of PCa management. We recommend more cost analyses to be performed in the Canadian setting, especially for the newer treatments for PCa.
METHODS: A systematic review was conducted across Embase, MEDLINE, CINHAL, Web of Science and grey literature of studies presenting Canadian costs of PCa management. Eligible studies included studies presenting direct or indirect Canadian costs of PCa management, including pharmacological or non-pharmacological treatments, adverse events management and diagnosis. The CHEC criteria list was used for quality assessment of the studies. Study selection, data extraction and quality assessment were conducted independently by two reviewers. Costs were standardized to 2023 Canadian dollars using the Statistic Canada’s Consumer Price Index for health and personal care.
RESULTS: 28 studies were retrieved and analyzed. Costs presented covered various aspects of PCa management like radical prostatectomy (8 studies, $9,123.86 - $24,583.19 per case), radiation therapy (10 studies, $4,156.21 - $21,388.73 per case), androgen deprivation therapy (6 studies, $4,560.21 - $41,776.08 per year) or management of metastatic bone disease (3 studies, $6,490.37 - $27,078.37 per year). While the more ancient management methods are well documented, literature remains sparse when it comes to the new treatments for PCa like enzalutamide (2 studies, $26,653.32 - $47,351.08 per year) or abiraterone (2 studies, $47,336.16 - $53,547.92).
CONCLUSIONS: This is the first systematic review of Canadian costs of PCa management since 2013. Even though the data on the newer therapies is still limited, we can conclude that they are costlier and add to the economic burden of PCa management. We recommend more cost analyses to be performed in the Canadian setting, especially for the newer treatments for PCa.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE454
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Oncology